Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-24
2006-10-24
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S141000, C546S146000, C546S314000, C546S315000, C544S277000, C544S258000, C562S622000, C562S623000, C514S314000, C514S249000, C514S261100, C514S268000, C514S307000
Reexamination Certificate
active
07126001
ABSTRACT:
The present invention provides the compound having the formula:wherein each of R1and R2is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
REFERENCES:
patent: 2279560 (1942-04-01), Dietrich
patent: 2346665 (1944-04-01), Cupery
patent: 2895991 (1959-07-01), Randall et al.
patent: 3450676 (1969-06-01), McKillip
patent: 3632783 (1972-01-01), Stonis
patent: 3875301 (1975-04-01), Windheuser
patent: 4056524 (1977-11-01), Walker
patent: 4442305 (1984-04-01), Weitl et al.
patent: 4480125 (1984-10-01), Haas et al.
patent: 4537781 (1985-08-01), Darling
patent: 4611053 (1986-09-01), Sasa
patent: 4614815 (1986-09-01), Cognigni et al.
patent: 4801748 (1989-01-01), Murahashi et al.
patent: 4863967 (1989-09-01), Hall et al.
patent: 4882346 (1989-11-01), Driscoll et al.
patent: 4935450 (1990-06-01), Cone, Jr.
patent: 4983636 (1991-01-01), Takeuchi et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5330744 (1994-07-01), Pontremoli et al.
patent: 5366982 (1994-11-01), Dereu et al.
patent: 5668179 (1997-09-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5846960 (1998-12-01), Labrie
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0018968 (2004-01-01), Sgouros et al.
patent: 2004/0087657 (2004-05-01), Richon et al.
patent: 26 35 558 (1977-02-01), None
patent: 0 014 230 (1980-08-01), None
patent: 0 137 640 (1985-04-01), None
patent: 0 169 645 (1986-01-01), None
patent: 0 226 304 (1987-06-01), None
patent: 0 594 577 (1998-12-01), None
patent: 1 010 705 (2000-06-01), None
patent: 1502573 (1978-03-01), None
patent: 02 219589 (1990-09-01), None
patent: WO 99/11659 (1990-09-01), None
patent: WO 95/31977 (1995-11-01), None
Das, M.K., et al., “Synthesis of Some Dihydroxamic Acid Siderophores,”Chemical Abstracts, 101(7):582 (1984). (FromJ. Chem. Eng. Data, 1984, 29(3):345-348, Abstract No. 54665t).
Chun, H.G., et al., “Hexamethylene Bisacetamide: A Polar-Planar Compound Entering Clinical Trials as a Differentiating Agent,”Cancer Treatment Reports, 70(8):991-996 (1986).
Brown, D., et al., “A Facile Synthesis of Aliphatic Dihydroxamic Acids of General Formula RONR1-CO-(CH2)n-CO-NR1OR,”23-Aliphatics, 105:605 (1986). (FromSynth. Commun., 1985, 15(13):1159-1164, Abstract No. 78501v).
Brown, D.A., et al., “Design of Metal Chelates with Biological Activity. 5. Complexation Behavior of Dihydroxamic Acids with Metal Ions,”Inorganic Chemistry, 25(21):3792-3796 (1986).
Linfield, W.M., et al., “Antibacterially Active Substituted Anilides of Carboxylic and Sulfonic Acids,”J. Med. Chem., 26(12):1741-1746 (1983).
Lea, M.A., and Tulsyan N., “Discordant Effects of Butyrate Analogues on Erythroleukemia Cell Proliferation, Differentiation and Histone Deacetylase,”Anti Cancer Research, 15:879-883 (1995).
Kwon, H.J., et al., “Depudecin Induces Morphological Reversion of Transformed Fibroblasts via the Inhibition of Histone Deacetylase,”Proc. Natl. Acad. Sci. USA, 95(7):3356-3361 (1998).
Kim, Y.B., et al., “Oxamflatin is a Novel Antitumor Compound that Inhibits Mammalian Histone Deacetylase,”Oncogene, 18:2461-2470 (1999).
Kijima, M., et al., “Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase,”The Journal of Biological Chemistry, 268(30):22429-22435 (1993).
Iwata, S., and Hirai, K., “Polyurethanes with Small Permanent Compressive Strain and Their Moldings,”Chemical Abstracts, 125(18):28. (From Jpn. Kokai Tokkyo Koho JP 08,176,264 [96,176,264], 1996, Abstract No. 222822h.).
Hynes, J.B., “Hydroxylamine Derivatives as Potential Antimalarial Agents. 1. Hydroxamic Acids,”Jour. of Medicinal Chem., 13(6):1235-1237 (1970).
Hozumi, T., et al., “Induction of Erythroid Differentiation in Murine Erythroleukemia Cells by N-Substituted Polymethylene Diamides,”Int. J. Cancer, 23:119-122 (1979).
Hozumi, T., et al., “Induction of Erythroid Diffeerentiation in Murine Erythroleukemia Cells by Nitrogen Substituted Polymethylene Diamides,” ChemicalAbstracts, 90(13). ( FromInt. J. Cancer, 23(1) :119-122, 1979) Abstract No. 1162482.
Haces, A., et al., “Chemical Differentiating Agents. Differentiation of HL-60 Cells by Hexamethylenebis [acetamide] Analogues,”J. Med. Chem., 30(2):405-409 (1987).
Fibach, E., et al., “Effect of Hexamethylene Bisacetamide on the Commitment to Differentiation of Murine Erythroleukemia Cells,”Cancer Research, 37:440-444 (1977).
Egorin, M.J., et al., “Phase I Clinical and Pharmacokinetic Study of Hexamethylene Bisacetamide (NSC 95580) Administered as a Five-Day Continuous Infusion,” Cancer Research, 47:617-623 (1987).
Yoshida, M., et al., “Potent and Specific Inhibition of Mammalian Histone Deacetylase Bothin Vivoandin Vitroby Trichostatin A,”J. of Biol. Chem., 265 (28):17174-17179 (1990).
Weitl, F., and Raymond, K.N., “Lipophilic Enterobactin Analogues1. Terminally N-Alkylated Spermine/Spermidine Catecholcarboxamides,”J. Org. Chem., 46:5234-5237 (1981).
Toi, K., and Izumi, Y., “Stereoisomers of alpha, alpha-diaminoadipic Acid,”Chemical Abstract, CAOLD Accession No. CA55:6371e (1955).
Tanaka, M., et al., “Induction of Erythroid Differentiation in Murine Virus Infected Erythroleukemia Cells by Highly by Highly Polar Compounds,” Proc. Nat. Acad. Sci. USA, 72(3):1003-1006 (1975).
Tabernero, E., et al., “Antitrypansomal (T. Venezuelense) and Antimycotic Effects of Various Hydroxamic Acids,”1-Pharmacology, 98:27, 1983. (FromActa Cient. Venez., 32 (5):411-416, 1981).
Saito, A., et al., “A Synthetic Inhibitor of Histone Deacetylase, MS-27-275, with Markedin VivoAntitumor Activity Against Human Tumors,”Proc. Natl. Acad. Sci. USA, 96:4592-4597 (1999).
Rifkind, R.A., and Marks, P.A., “Regulation of Differentiation in Transformed Erythroid Cells,”Blood Cells, 4:189-206 (1978).
Richon, V.M., et al., “A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases,” Proc. Natl. Acad. Sci. USA, 95:3003-3007 (1998).
Reuben, R.C., et al. “A New Group of Potent Inducers of Differentiation in Murine Erythroleukemia Cells,”Proc. Natl. Acad. Sci. USA, 73 (3):862-866 (1976).
Morrison, R.T., and Boyd, R.N., “Conversion of Amines Into Substituted Amides.” InOrganic Chemistry(3rdEdition, Allyn and Bacon, Boston, Massachusetts), pp. 755-758 (1973).
Melloni, E., et al., “Vincristine-Resistant Erythroleukemia Cell Line has Marked Increased Sensitivity to Hexamethylenebisacetamide-Induced Differentiation,”Proc. Natl. Acad. Sci. USA, 85:3835-3839 1988).
Marks, P.A., et al., “Polar/Apolar Chemical Inducers of Differentiation of Transformed Cells: Strategies to Improve Therapeutic Potential,”Proc. Natl. Acad. Sci. USA, 86:6358-6362 (1989).
Marks, P.A., and Rifkind, R.A., “Hexamethylene Bisacetamide-Induced Differentiation of Transformed Cells: Molecular and Cellular Effects and Therapeutic Application,”Int. J. of Cell Cloning, 6:230-
Belvedere Sandro
Breslow Ronald
Gershell Leland
Marks Paul A.
Miller Thomas A.
Elrifi, Esq. Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo PC
Seaman D. Margaret
Sloan-Kettering Institute for Cancer Research
The Trustees of Columbia University in the City of New York
LandOfFree
Class of cytodifferentiating agents and histone deacetylase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Class of cytodifferentiating agents and histone deacetylase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Class of cytodifferentiating agents and histone deacetylase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3664918